Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Allogene Therapeutics Inc | ALLO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.46 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.46 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.23 - 6.89 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.46 | USD |
Allogene Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 585.06M | 169.09M | - | 95k | -327.27M | -1.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Allogene Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALLO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.98 | 4.0062 | 3.395 | 3.60 | 1,923,330 | -0.52 | -13.07% |
| 1 Month | 4.39 | 4.63 | 3.395 | 3.99 | 1,614,663 | -0.93 | -21.18% |
| 3 Months | 3.23 | 5.775 | 3.12 | 4.43 | 2,311,445 | 0.23 | 7.12% |
| 6 Months | 3.08 | 5.775 | 2.23 | 3.51 | 2,621,991 | 0.38 | 12.34% |
| 1 Year | 4.73 | 6.89 | 2.23 | 4.13 | 2,425,917 | -1.27 | -26.85% |
| 3 Years | 32.01 | 35.88 | 2.23 | 9.19 | 1,943,792 | -28.55 | -89.19% |
| 5 Years | 25.65 | 55.00 | 2.23 | 13.77 | 1,444,253 | -22.19 | -86.51% |
Allogene Therapeutics Description
| Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. |
